Brokerage Firm Rating Update on Jazz Pharmaceuticals plc (JAZZ)

Jazz Pharmaceuticals plc (JAZZ) : Zacks Investment Research ranks Jazz Pharmaceuticals plc (JAZZ) as 5, which is a Strong Sell recommendation. 11 research analysts consider that the stocks fundamentals point to a bright future, hence they rate the stock as a Strong Buy. A total of 1 analysts believe that the stock has a limited upside, hence they advise a Hold. The average broker rating of 12 research analysts is 1.17, which indicates as a Strong Buy.

Jazz Pharmaceuticals plc (JAZZ) : 11 Wall Street analysts covering Jazz Pharmaceuticals plc (JAZZ) believe that the average level the stock could reach for the short term is $184.18. The maximum price target given is $210 and the minimum target for short term is around $145, hence the standard deviation is calculated at $20.18.


For the current week, the company shares have a recommendation consensus of Buy. Also, Janney Capital initiates coverage on Jazz Pharmaceuticals plc (NASDAQ:JAZZ). Janney Capital has a Neutral rating on the shares. The rating by the firm was issued on August 25, 2016.

Jazz Pharmaceuticals plc (NASDAQ:JAZZ): The stock opened at $121.42 and touched an intraday high of $123.63 on Wednesday. During the day, the stock corrected to an intraday low of $121.08, however, the bulls stepped in and pushed the price higher to close in the green at $121.92 with a gain of 0.41% for the day. The total traded volume for the day was 643,527. The stock had closed at $121.42 in the previous trading session.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.